SCHEMBL2397770

SCHEMBL2397770

O=C(Cl)c1c(F)cc(Cl)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 1/20 0.38
SPR P35270 1/20 0.37
TPMT P51580 1/20 0.37
GAA P10253 1/20 0.35
CES2 O00748 4/20 0.34
CES1 P23141 4/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA4 P22748 2/20 0.34
KMT2A Q03164 1/20 0.34
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
GRM2 Q14416 1/20 0.33
SLC2A1 P11166 1/20 0.33
TSHR P16473 1/20 0.33
MAP2 P11137 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
HCAR1 Q9BXC0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20639027 0.89 ALDH1A1 (0.41) ALDH1A1ALOX15SPRTPMTGAA
SCHEMBL289690 0.82 CES2 (0.44) ALDH1A1ALOX15SPRGAACES2
SCHEMBL3031058 0.80 TPMT (0.48) ALDH1A1ALOX15SPRTPMTKEAP1
SCHEMBL9712503 0.78 HDAC1 (0.38) ALDH1A1ALOX15TPMTGAACA1
SCHEMBL3024877 0.78 GRM2 (0.42) SPRTPMTGAAGRM2MAP2
SCHEMBL1085223 0.78 DGAT1 (0.41) ALDH1A1ALOX15GAACES2CES1
SCHEMBL3028979 0.78 NPC1 (0.41) ALDH1A1SPRTPMTGAACA1
SCHEMBL23764727 0.76 LMNA (0.44) ALDH1A1ALOX15TPMTCES2CES1
Hydrochloric Acid SCHEMBL11874647 0.76 ALDH1A1 (0.35) ALDH1A1ALOX15CES2CES1CA1
SCHEMBL29924838 0.75 GSK3B (0.43) ALDH1A1SPRTPMTGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333406-A1 SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYSOWAY THERAPEUTICS INC (US) 2025-10-30 US disclosed
CN-117567508-A Bisphosphonate containing hydroxamic acid and preparation method and application thereof 华中师范大学 2024-02-20 CN disclosed
EP-2173724-B1 QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE INC (US) 2012-12-05 EP disclosed
US-8232285-B2 Quinazolinone compounds and methods of use thereof ARQULE, INC. (US) 2012-07-31 US disclosed
US-20110217300-A1 Quinazolinone Compounds and Methods of Use Thereof ARQULE, INC. (US) 2011-09-08 US disclosed
EP-2173724-A2 QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF ArQule, Inc. (US) 2010-04-14 EP disclosed
US-20090130097-A1 Quinazolinone Compounds and Methods of Use Thereof ARQULE, INC. (US) 2009-05-21 US disclosed
WO-2009002808-A2 QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110217300-A1 Quinazolinone Compounds and Methods of Use Thereof NQO2, NQO1, MKI67 ALDH1A1 352/4885ALOX15 1190/4885SPR 1677/4885
US-20090130097-A1 Quinazolinone Compounds and Methods of Use Thereof NQO2, NQO1, MKI67 ALDH1A1 352/4885ALOX15 1190/4885SPR 1677/4885
US-20250333406-A1 SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF STOML2, ATP2A3, ATP2A1 ALDH1A1 3204/4885ALOX15 3108/4885SPR 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.